This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Rite Aid (RAD) to Report Q2 Earnings: What Should You Know?
by Zacks Equity Research
Rite Aid (RAD) is likely to have gained from PBM, RxEvolution strategy and expanded omnichannel services in Q2. Rising wage costs and drab front-end same-store sales are likely to have been concerns.
Walgreens Boots Alliance (WBA) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $49.62, moving -0.64% from the previous trading session.
Can Walgreens (WBA) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Walgreens (WBA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Retail and Wholesale Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $49.94, moving -0.36% from the previous trading session.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $50.57, moving -1.02% from the previous trading session.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $51.29, marking a -0.95% move from the previous day.
Stock Market News for Sep 3, 2021
by Zacks Equity Research
Benchmarks closed in the green on Thursday as investors rejoiced improvement in weekly jobless claims ahead of August's jobs data scheduled for release on Friday.
Stock Market News for Sep 1, 2021
by Zacks Equity Research
Benchmarks closed in the red on Tuesday as investors await jobs data for August scheduled for release on Sep 3 to trace when the Federal Reserve may begin tapering its bond purchases.
Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact
by Zacks Equity Research
Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $48.48 in the latest trading session, marking a +1.34% move from the prior day.
Walgreens (WBA) Provides Flu Shots Nationwide for Ages 3 & More
by Zacks Equity Research
Walgreens (WBA) is ready to co-administer COVID-19 vaccines and flu shots anticipating COVID-19 boosters in September.
Stock Market News for Aug 12, 2021
by Zacks Equity Research
U.S. stock markets closed mostly higher on Wednesday after Senate Democrats passed a budget resolution for the $3.5 trillion bill.
Stock Market News for Aug 5, 2021
by Zacks Equity Research
The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
Top Research Reports for Johnson & Johnson, Oracle & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Oracle (ORCL), and SAP SE (SAP).
McKesson (MCK) Enters Deal to Divest Some European Businesses
by Zacks Equity Research
McKesson (MCK) to sell off some of its European ventures to streamline its business and prioritize investments in areas where it has better expertise.
Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal
by Zacks Equity Research
With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.
Zacks Industry Outlook Highlights: CVS Health, Walgreen Boots, Herbalife and Amazon
by Zacks Equity Research
Zacks Industry Outlook Highlights: CVS Health, Walgreen Boots, Herbalife and Amazon
Bear of the Day: Rite Aid (RAD)
by David Bartosiak
The competition is fierce and earnings are moving in the wrong direction
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Pandemic Woes
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry is gaining from growing demand for digital healthcare support. Industry players CVS, WBA and HLF are set to gain the most. However, Amazon's entry threat disrupts this uptrend.
Company News for Jul 2, 2021
by Zacks Equity Research
Companies in The News Are: WBA, UAL, MKSI, ATC, SMPL.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Walgreens Boots (WBA) revenues improve 12.1% year-over-year in the third quarter on robust growth in the International and United States segments.
Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe
by Zacks Equity Research
Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.
Why Walgreens Boots Alliance (WBA) Might Surprise This Earnings Season
by Zacks Equity Research
Walgreens Boots Alliance (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.